查看文章

We aimed to elucidate predictive factors for the development of immune-related adverse events (ir aes) in patients receiving immunotherapies for the management of advanced solid cancers. This retrospective study involved all patients with histologically confirmed metastatic or inoperable melanoma, non-small-cell lung cancer, or renal cell carcinoma receiving immunotherapy at the Cancer Centre of Southeastern Ontario. The type and severity of ir aes, as well as potential protective and exacerbating factors, were collected from patient charts. The study included 78 patients receiving ipilimumab (32%), nivolumab (33%), or pembrolizumab (35%). Melanoma, non-small-cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the cancers in the study population. In 41 patients (53%) ir aes developed, with multiple ir aes developing in 12 patients (15%). In most patients (70%), the ir aes were of severity grade 1 or 2. Female sex [adjusted odds ratio (or adj): 0.094; 95% confidence interval (ci): 0.021 to 0.415; p= 0.002] and corticosteroid use before immunotherapy (or adj: 0.143; 95% ci: 0.036 to 0.562; p= 0.005) were found to be associated with a protective effect against ir aes. In contrast, a history of autoimmune disease (or adj: 9.55; 95% ci: 1.34 to 68.22; p= 0.025), use of ctla-4 inhibitors (or adj: 6.25; 95% ci: 1.61 to 24.25; p= 0.008), and poor kidney function of grade 3 or greater (or adj: 10.66; 95% ci: 2.41 to 47.12; p= 0.025) were associated with a higher risk of developing ir aes. A Hosmer–Lemeshow goodness-of-fit test demonstrated that the logistic regression model was effective at predicting the …